Cargando…

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krzyzanowska, Monika K, Julian, Jim A, Gu, Chu-Shu, Powis, Melanie, Li, Qing, Enright, Katherine, Howell, Doris, Earle, Craig C, Gandhi, Sonal, Rask, Sara, Brezden-Masley, Christine, Dent, Susan, Hajra, Leena, Freeman, Orit, Spadafora, Silvana, Hamm, Caroline, Califaretti, Nadia, Trudeau, Maureen, Levine, Mark N, Amir, Eitan, Bordeleau, Louise, Chiarotto, James A, Elser, Christine, Husain, Juhi, Laferriere, Nicole, Rahim, Yasmin, Robinson, Andrew G, Vandenberg, Ted, Grunfeld, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652580/ https://www.ncbi.nlm.nih.gov/pubmed/34880055 http://dx.doi.org/10.1136/bmj-2021-066588

Ejemplares similares

Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol
por: Krzyzanowska, Monika K., et al.
Publicado: (2019)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

User-Centered Design of a Web-Based Tool to Support Management of Chemotherapy-Related Toxicities in Cancer Patients
por: Prince, Rebecca M, et al.
Publicado: (2019)

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2018)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma – significance of potentially retained stemness
por: Yoon, Ju-Yoon, et al.
Publicado: (2020)

Autophagic Heterogeneity in Gastric Adenocarcinoma
por: Yoon, Ju-Yoon, et al.
Publicado: (2021)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
por: Yoon, Ju-Yoon, et al.
Publicado: (2019)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments
por: Peng, J., et al.
Publicado: (2019)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
por: Covelli, Andrea, et al.
Publicado: (2019)

Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study
por: Moskalewicz, Alexandra, et al.
Publicado: (2022)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
por: Lee, Michelle C. M., et al.
Publicado: (2021)

Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis
por: Naseem, Madiha, et al.
Publicado: (2015)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology
por: Lenihan, Daniel J., et al.
Publicado: (2019)

State Anxiety Impairs Proactive but Enhances Reactive Control
por: Yang, Youcai, et al.
Publicado: (2018)

The Integrated Proactive Surveillance System for Prostate Cancer
por: Wang, Haibin, et al.
Publicado: (2012)

Impact of a Training Program on Oncology Nurses’ Confidence in the Provision of Self-Management Support and 5As Behavioral Counseling Skills
por: Howell, Doris, et al.
Publicado: (2023)

Proactive control of proactive interference using the method of loci
por: Bass, Willa S., et al.
Publicado: (2014)

Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study
por: Maxwell, Cynthia, et al.
Publicado: (2021)

Do you feel like being proactive today? Trait-proactivity moderates affective causes and consequences of proactive behavior
por: Wolsink, Inge, et al.
Publicado: (2019)

The Impact of Leader Proactivity on Follower Proactivity: A Chain Mediation Model
por: Zhang, Kaixin, et al.
Publicado: (2022)

Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer
por: Krzyzanowska, Monika K., et al.
Publicado: (2019)

Proactive integrated virtual healthcare resource use in primary care
por: Haun, Jolie N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2oncbp6meiqvk2slakfg5j9j15